MDT

100.58

-1.14%↓

A

134.59

-3.4%↓

VEEV

221.73

-1.03%↓

HQY

84.73

-2.01%↓

NEOG

9.73

-2.41%↓

MDT

100.58

-1.14%↓

A

134.59

-3.4%↓

VEEV

221.73

-1.03%↓

HQY

84.73

-2.01%↓

NEOG

9.73

-2.41%↓

MDT

100.58

-1.14%↓

A

134.59

-3.4%↓

VEEV

221.73

-1.03%↓

HQY

84.73

-2.01%↓

NEOG

9.73

-2.41%↓

MDT

100.58

-1.14%↓

A

134.59

-3.4%↓

VEEV

221.73

-1.03%↓

HQY

84.73

-2.01%↓

NEOG

9.73

-2.41%↓

MDT

100.58

-1.14%↓

A

134.59

-3.4%↓

VEEV

221.73

-1.03%↓

HQY

84.73

-2.01%↓

NEOG

9.73

-2.41%↓

Search

Embecta Corp

Avatud

SektorTervishoid

11.26 -8.08

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.23

Max

12.17

Põhinäitajad

By Trading Economics

Sissetulek

-19M

26M

Müük

-32M

264M

P/E

Sektori keskmine

7.648

89.037

Dividenditootlus

4.76

Kasumimarginaal

10

Töötajad

1,850

EBITDA

-40M

71M

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.76%

2.18%

Järgmine tulemuste avaldamine

5. veebr 2026

Järgmine dividendimakse kuupäev

13. märts 2026

Järgmine aktsia dividendi kuupäev (ex-date)

27. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

-61M

734M

Eelmine avamishind

19.34

Eelmine sulgemishind

11.26

Uudiste sentiment

By Acuity

50%

50%

174 / 360 Pingereas Healthcare

Embecta Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. jaan 2026, 21:55 UTC

Tulu

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22. jaan 2026, 23:52 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22. jaan 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22. jaan 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22. jaan 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. jaan 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22. jaan 2026, 22:37 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22. jaan 2026, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22. jaan 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

22. jaan 2026, 21:44 UTC

Tulu

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22. jaan 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22. jaan 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22. jaan 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22. jaan 2026, 21:30 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Capital One To Acquire Brex >COF

22. jaan 2026, 21:13 UTC

Tulu

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22. jaan 2026, 21:11 UTC

Tulu

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22. jaan 2026, 21:11 UTC

Tulu

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22. jaan 2026, 21:10 UTC

Tulu

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22. jaan 2026, 21:06 UTC

Tulu

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Rev $15.58B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q EPS $3.26 >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net Interest Margin 8.26% >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net $2.13B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Adj EPS $3.86 >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net Charge-Offs $3.8B >COF

22. jaan 2026, 21:05 UTC

Tulu

Intuitive Surgical 4Q EPS $2.21 >ISRG

Võrdlus sarnastega

Hinnamuutus

Embecta Corp Prognoos

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

0

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

174 / 360 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Embecta Corp

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
help-icon Live chat